BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 14574460)

  • 1. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
    Rockwell S; Kelley M
    Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors.
    Donnelly ET; Liu Y; Rockwell S
    Exp Biol Med (Maywood); 2006 Mar; 231(3):317-21. PubMed ID: 16514179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
    Teicher BA; Holden SA; Ara G; Dupuis NP; Goff D
    Cancer J Sci Am; 1995; 1(1):43-8. PubMed ID: 9166453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
    Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
    Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
    Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
    Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
    Rockwell S
    J Natl Cancer Inst; 1983 Oct; 71(4):765-71. PubMed ID: 6413743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
    Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
    In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
    Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E
    Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells.
    Laurencot CM; Kennedy KA
    Oncol Res; 1995; 7(7-8):371-9. PubMed ID: 8747600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
    Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
    Vink SR; Lagerwerf S; Mesman E; Schellens JH; Begg AC; van Blitterswijk WJ; Verheij M
    Clin Cancer Res; 2006 Mar; 12(5):1615-22. PubMed ID: 16533789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
    Masunaga S; Ono K; Hori H; Akaboshi M; Kawai K; Suzuki M; Kinashi Y; Kasai S; Nagasawa H; Uto Y
    Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.